Pediatric Atopic Dermatitis Treatment Selection
Experts discuss the recent FDA approval of topical JAK inhibitors for children 2 years or older as a promising advancement in pediatric atopic dermatitis treatment.
They highlight their efficacy, safety, and the practical challenges of integrating these options into individualized care plans, emphasizing the importance of patient education, access, and ongoing monitoring.
The recent FDA approval of topical JAK inhibitors for children 2 years or older marks a significant advancement in pediatric atopic dermatitis treatment.
Experts emphasize the need for patient education, access, and ongoing monitoring when using these new treatment options.
Author's summary
Topical JAK inhibitors offer new hope for pediatric atopic dermatitis treatment.